3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
104
Breast
7
Dermatologic
3
Thoracic
2
Plasma cell
2
Head & Neck
2
Genitourinary
2
Gastrointestinal
2
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Sarcoma
13
Sarcoma, Kaposi
4
Sarcoma, Ewing
4
Leiomyosarcoma
4
Rhabdomyosarcoma
3
Osteosarcoma
3
Liposarcoma
3
Breast Neoplasms
3
AIDS-related Kaposi sarcoma
3
Sarcoma, Synovial
2
Pancreatic Neoplasms
2
Histiocytoma, Malignant Fibrous
2
Acquired Immunodeficiency Syndrome
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multi-centric Castleman's Disease
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Desmoid Tumors
1
Interventions
Filgrastim
14
Cyclophosphamide
13
Carboplatin
12
Paclitaxel
8
Ifosfamide
8
Doxorubicin
8
pembrolizumab
7
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
fludarabine
5
Temozolomide
5
Specimen Handling
5
Radiotherapy
5
Cisplatin
5
Magnetic Resonance Spectroscopy
4
Etoposide
4
Docetaxel
4
Amifostine
4
aldesleukin
3
Trastuzumab
3
Taxes
3
Psychiatric Rehabilitation
3
Melphalan
3
Fulvestrant
3
Bevacizumab
3
sodium thiosulfate
2
pazopanib
2
pamiparib
2
palbociclib
2
etoposide phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
liposomal doxorubicin
×
Sarcoma
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled